About ImmunSYS
ImmunSYS is a Healthcare company based in Delray Beach (United States) founded in 2018. Immunotherapeutics drugs and devices for prostate cancer are developed. ImmunSYS has raised $5.48 million across 2 funding rounds. ImmunSYS offers products and services including YourVaccx™ and ANTIGENerator™. Its focus areas include Life Sciences, Immunotherapy, Vaccine and Therapeutic. Its legal entity is ImmunSYS, Inc. Its competitors include Imvax, BriaCell Therapeutics and Radionetics; 2 of its 3 listed competitors have raised funding.
Company details
ImmunSYS was founded in 2018 in Delray Beach, United States, with operations centered in the biotechnology sector. Development efforts are directed toward immunotherapeutics drugs and devices targeting late-stage metastatic prostate cancer. The lead candidate, MyVaccx, is advanced as a clinical-stage immunotherapeutic agent. This involves integration of a proprietary antigen presentation medical device system and intra-tumoral injection of a depot drug formulation containing immunotherapeutics and an immunostimulant.
- Headquarters Delray Beach, United States
- SectorsHealthcare
- Email••••••••
- Website immunsys.com
- Social X
- Legal Name Immunsys, Inc.
- Total Equity Funding$5.48M (USD)
in 2 rounds
- Latest Funding Round$283.27K (USD), Series A
Apr 2020
Products & Services of ImmunSYS
ImmunSYS offers a comprehensive portfolio of products and services, including YourVaccx™ and ANTIGENerator™.
Therapy empowering immune system to attack metastatic cancer cells.
Device that lyses tumor cells to release antigens for immunotherapy.
Funding Insights of ImmunSYS
ImmunSYS has successfully raised a total of $5.48M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $283.27 thousand completed in April 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $5.48M
- Total Rounds 2
- Last Round Series A — $283,270
- First Round $5.2M
(Oct 2019)
All 2 funding rounds of ImmunSYS with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2020 | $283,270 | Series A | – | – | – |
| Oct 2019 | $5.2M | Series A | – | – | – |
People of ImmunSYS
11 people are tracked at ImmunSYS (3 in leadership, 7 in board & advisors, 1 in team).
| Name | Role | Group |
|---|---|---|
Igor Keselman | President & CEO | Leadership |
Gary M. Onik | CFO | Leadership |
Alex Dolgonos | Chief Strategy Officer | Leadership |
David Crawford | Advisor | Board & advisors |
Donald L. Trump | Advisor | Board & advisors |
Neal D. Shore | Advisor | Board & advisors |
Steven O’Day | Advisor | Board & advisors |
George Prendergast | Advisor | Board & advisors |
Richard Mark Friedhoff | Patient Advocate | Board & advisors |
Timothy P. Murphy | Advisor | Board & advisors |
David Bostwick | CSO | Team |
Complete people profiles for ImmunSYS
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of ImmunSYS
3 dated milestones of ImmunSYS across 2 years, from founding to its latest funding, stage changes and deals.
- Founded ImmunSYS is founded.
- Funding First funding round of $5.2M.
- Funding Latest funding round, Series A, of $283K.
Competitors of ImmunSYS
ImmunSYS has 3 listed competitors in our database, 2 of them funded. They include Imvax, BriaCell Therapeutics and Radionetics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| imvax.com | 2015 | Philadelphia, United States | $203.83M | 50 | Patient-specific cell vaccines for glioma treatment are developed. | |
| briacell.com | 2004 | Beverly Hills, United States | 16 | Developer of immunotherapies for the treatment of cancer | ||
| radionetics.com | 2021 | San Diego, United States | $136.71M | Peptide-targeted radiopharmaceuticals for cancer treatment are developed. |
Detailed competitors of ImmunSYS
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Immunology & Cancer Therapeutics
3 companies that operate in the same segment as ImmunSYS (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | |||
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Immunsys
Complete news archive for ImmunSYS
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about ImmunSYS
ImmunSYS was founded in 2018 and raised its 1st funding round 1 year after it was founded.
ImmunSYS is headquartered in Delray Beach, United States. It is registered at Delray Beach, Florida, United States.
ImmunSYS is a funded company, having raised a total of $5.48M across 2 funding rounds to date. The company's 1st funding round was a Series A of $5.2M, raised on Oct 2019.
ImmunSYS was founded in 2018 in Delray Beach, United States, with operations centered in the biotechnology sector. Development efforts are directed toward immunotherapeutics drugs and devices targeting late-stage metastatic prostate cancer. The lead candidate, MyVaccx, is advanced as a clinical-stage immunotherapeutic agent. This involves integration of a proprietary antigen presentation medical device system and intra-tumoral injection of a depot drug formulation containing immunotherapeutics and an immunostimulant.
ImmunSYS's top competitors include Imvax, BriaCell Therapeutics and Radionetics.
ImmunSYS offers YourVaccx™ and ANTIGENerator™.
ImmunSYS operates through Immunsys, Inc..